Bill of Health

MAY 22, 2023

Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019. Trends in Spending and Claims for P2Y12 Inhibitors by Medicare and Medicaid From 2015 to 2020. A full posting of abstracts/summaries of these articles may be found on our  website.

Pharmaceutical Industry 157

Pharmaceutical Industry Medicare Medicare Medicaid 157

HIT Consultant

SEPTEMBER 14, 2023

Samm Anderegg, Co-Founder & CEO at DocStation Early next year, the Centers for Medicare and Medicaid Services (CMS) will remove the application of retroactive DIR fees and move DIR fees to the point of sale instead. What opportunities will AI offer the pharmaceutical industry to make further progress concerning PBMs and their DIR fees?

Pharmaceutical Industry 59

Pharmaceutical Industry Medicaid Medicaid Medicare 59

HIT Consultant

OCTOBER 20, 2023

can be attributed to falls, including approximately six percent of Medicare and eight percent of Medicaid expenditures. Fornari co-founded and was the CEO and medical director of Dominion Diagnostics, one of the country’s leading pharmaceutical monitoring laboratories and served there from 1997 to 2011.

Pharmaceutical Industry 105

Pharmaceutical Industry Public Health Medicaid Medicaid 105

Healthcare IT Today

JANUARY 8, 2024

The AI revolution has been and will continue to redefine the pharmaceutical industry in 2024, promising transformative outcomes for patients. Jason Rose, CEO at Adhere Health 2024 will spark transformational change across the pharmaceutical industry. Dave Latshaw, CEO at BioPhy 1.

Pharmaceutical Industry 89

Pharmaceutical Industry Due Diligence Compliance Regulatory Compliance 89

Fierce Healthcare

AUGUST 29, 2023

The Biden administration and federal regulators may be taking a victory lap following the unveiling of the Centers for Medicare & Medicaid Services’ (CMS') price negotiations list, but major pl | Critics of President Joe Biden's policies to rein in prices for 10 Medicare Part D drugs believe the policy is "draconian" and will (..)

Pharmaceutical Industry 96

Pharmaceutical Industry Medicare Medicare Medicaid 96

Health Populi

MARCH 11, 2021

At the end of this day, something Muna Bhanji, an advisor to biopharmaceutical developers who spent over 30 years of her career with Merck, noted: no advances toward value-based care will happen without a sense of partnership, requiring aligned incentives across the health/care ecosystem.

Health Insurance 98

Health Insurance ACA Medicare Medicare 98

Bill of Health

SEPTEMBER 12, 2023

SB: Both Medicaid and the Title X program go a long way to making contraceptives available, and these same issues have to be worked out by those programs. JRJ: Now, looking to the future of pharmaceutical regulation, the FDA approval of Opill is a significant milestone, from a legal or regulatory perspective.

FDA 184

FDA Pharmaceutical Industry COVID-19 Public Health 184